A., Lichter, S., & Swartz, M
We are excited to work closely with the world-class scientific teams at Daiichi Sankyo. Read the full story here: To view or add a comment, sign in AAX Biotech AB is excited to announce a collaboration with Daiichi Sankyo to evaluate Opti-mAb technology in next-generation antibody therapeutics
doi: 10.1016/j.nbd.2012.03.012
The findings do not undermine the efficacy of the drugs, experts say, but they need to be carefully considered by those paying for them and by patients considering their treatment options
The efficacy estimand represents efficacy had all randomized participants remained on study intervention (with possible dose interruptions and modifications) without initiating prohibited weight management treatments
The results showed a clear difference in the average weight loss achieved